Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/43048
Title: Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Authors: 
Issue Date: 2018
Citation: Br. J. Cancer.2018 11;(119)10:1208-1214
Abstract: Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was determined.
PMID: 30318515
URI: https://hdl.handle.net/20.500.12530/43048
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC6251034.pdf1.34 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.